VIAMET PHARMACEUTICALS

viamet-pharmaceuticals-logo

Viamet Pharmaceuticals discovers and develops "best-in-class" inhibitors of validated metalloenzymes via an innovative and proprietary metal-binding approach, their Metallophileรขโ€žยข Technology. Viamet's disruptive Metallophileรขโ€žยข technology is based on their world-class expertise in bioinorganic chemistry and metalloenzymes and allows them to identify validated targets with high therapeutic and commercial potential; leverage existing metalloenzyme inhibitors as the basis for Viamet's best-in-class analogs; and rapidly and cost-effectively generate best-in-class, patentable, small molecule compounds by optimizing the metal-binding component of existing inhibitors.

#People #Financial #Website #More

VIAMET PHARMACEUTICALS

Social Links:

Industry:
Biotechnology Medical Device Pharmaceutical

Founded:
2005-01-01

Address:
Morrisville, North Carolina, United States

Country:
United States

Website Url:
http://www.viamet.com

Total Employee:
11+

Status:
Closed

Contact:
(919) 467-8539

Email Addresses:
[email protected]

Total Funding:
120.2 M USD

Technology used in webpage:
Domain Not Resolving



Current Advisors List

douglas-reed_image

Douglas Reed Board of Directors @ Viamet Pharmaceuticals
Board_member

steve-hall_image

Steve Hall Board Observer @ Viamet Pharmaceuticals
Board_observer

lauren-silverman_image

Lauren Silverman Member of the Board of Directors @ Viamet Pharmaceuticals
Board_member

michael-dial_image

Michael Dial Board Observer @ Viamet Pharmaceuticals
Board_observer

s-edward-torres_image

S. Edward Torres Board of Directors @ Viamet Pharmaceuticals
Board_member

Current Employees Featured

not_available_image

Robert Schotzinger
Robert Schotzinger Chairman @ Viamet Pharmaceuticals
Chairman
2018-01-01

Founder


holden-thorp_image

Holden Thorp

not_available_image

Robert Schotzinger

Investors List

u-s-department-of-defense_image

U.S. Department of Defense

U.S. Department of Defense investment in Grant - Viamet Pharmaceuticals

intersouth-partners_image

Intersouth Partners

Intersouth Partners investment in Series D - Viamet Pharmaceuticals

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Series D - Viamet Pharmaceuticals

astellas-venture-management_image

Astellas Venture Management

Astellas Venture Management investment in Series D - Viamet Pharmaceuticals

lilly-ventures_image

Lilly Ventures

Lilly Ventures investment in Series D - Viamet Pharmaceuticals

hatteras-venture-partners_image

Hatteras Venture Partners

Hatteras Venture Partners investment in Series D - Viamet Pharmaceuticals

lurie-investment-fund_image

Lurie Investment Fund

Lurie Investment Fund investment in Series B - Viamet Pharmaceuticals

lilly-ventures_image

Lilly Ventures

Lilly Ventures investment in Series B - Viamet Pharmaceuticals

novartis-venture-fund_image

Novartis Venture Fund

Novartis Venture Fund investment in Series B - Viamet Pharmaceuticals

hatteras-venture-partners_image

Hatteras Venture Partners

Hatteras Venture Partners investment in Series B - Viamet Pharmaceuticals

Official Site Inspections

http://www.viamet.com

  • Host name: a29634cd52601a36f.awsglobalaccelerator.com
  • IP address: 99.83.138.213
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "Viamet Pharmaceuticals" on Search Engine